
Remix Therapeutics Advances Breakthrough Cancer Therapy with FDA Fast Track Designation for REM-422
Remix Therapeutics has achieved a significant regulatory milestone with the U.S. Food and Drug Administration granting Fast Track designation to REM-422, a first-in-class small molecule





















